Fig.5

Principal component analysis based on; (A) Estimated fecal bacterial products, inflammatory and gut integrity markers of HCMV infected infants (N = 15 each) with NC and healthy controls (N = 10); (B) Estimated fecal bacterial products, inflammatory and gut integrity markers and relative abundance of bacterial taxa of HCMV infected infants with NC (N = 15 each) and healthy controls (N = 10); (C) Estimated fecal bacterial products, inflammatory and gut integrity markers, relative abundance of bacterial taxa and relative frequencies of immune cell subsets of HCMV infected infants with NC (N = 9 each)